Loading
Life sciences · Journal article
Scientific Reports · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This study reports dose-dependent cytotoxicity of atractylenolide III against HepG2 cells in a single-arm in vitro assay, combined with computational screening to identify a putative molecular target (CD1b) and a structurally related lead compound. The work is presented as a framework-building exercise rather than a validated anticancer agent, and the authors explicitly state that cytotoxicity is preliminary pending future in vivo and mechanistic work.
Single-arm in vitro cytotoxicity screening with computational modeling. HepG2 hepatocellular carcinoma cells (no clinical subjects or in vivo models).. Intervention: Atractylenolide III at doses up to 25 µg/mL; computational screening of structurally related compounds..
Atractylenolide III achieved IC₅₀ of 15.50 µg/mL and reduced cell viability to 25.0% at 25 µg/mL in HepG2 cells Molecular docking identified binding affinity of −9.6 kcal/mol to CD1b across 76 cancer-associated proteins Pharmacophore screening of 1,513 structurally related compounds identified ZINC64701878 with superior binding affinity of −12.7 kcal/mol
No in vivo efficacy, toxicity, or pharmacokinetic data; no animal models tested Mechanism of cytotoxicity not experimentally validated; CD1b binding is computational prediction only
This work does not support clinical use or direct treatment decisions. It establishes a computational-experimental workflow for prioritizing marine natural products for further preclinical investigation in HCC drug discovery.
In vitro cytotoxicity screening with computational modeling of a marine natural product; no in vivo efficacy, mechanism validation, or clinical data; authors acknowledge cytotoxicity as initial support pending future investigations.
As stated by the source record.
Quoted from the source exactly as published.
This work does not support clinical use or direct treatment decisions. It establishes a computational-experimental workflow for prioritizing marine natural products for further preclinical investigation in HCC drug discovery.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Hepatocellular carcinoma (HCC) remains a major global health challenge, with over 900,000 new cases annually and a pronounced male predominance. In pursuit of novel, low-toxicity therapeutics, this study isolated Atractylenolide III from the marine coral Tubipora musica and demonstrated measurable, dose-dependent cytotoxic activity against HepG2 liver cancer cells, achieving an IC 50 value of 15.50 µg/mL and reducing cell viability to 25.0% at 25 µg/mL. To investigate potential molecular targets and propose hypothetical mechanism pathways, we employed a multi-layered computational strategy. Molecular docking across 76 cancer-associated proteins identified a strong binding affinity (-9.6 kcal/mol) with CD1b (PDB ID: 1GZP), a T-cell surface glycoprotein key to lipid antigen presentation and tumor immunology. Short-term molecular dynamics (MD) simulations were conducted to provide a preliminary structural-viability filter for this complex under physiological conditions. Pharmacophore modeling expanded the screening to 1,513 structurally related compounds, pinpointing ZINC64701878 as a superior candidate with enhanced binding affinity (-12.7 kcal/mol). Density functional theory (DFT) calculations supported its high reactivity, and pharmacokinetic profiling suggested favorable drug-likeness. Together, these findings propose a theoretical framework for marine-derived compounds as potential leads for HCC therapy. While the cytotoxicity assay provides initial phenotypic support, the primary contribution of this study lies in establishing a predictive computational-experimental framework to guide future in vivo and mechanistic investigations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.